Ensign Peak Advisors’s ACELYRIN SLRN Stock Holding History

Ensign Peak Advisors’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-100,000	Closed	-$1.02M	–	1760
2023 Q3	$1.02M	Hold	100,000	–	–	﹤0.01%	1195
2023 Q2	$2.09M	Buy	+100,000	New	+$2.05M	﹤0.01%	859

Other funds holding SLRN

ACMC

AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ensign Peak Advisors's SLRN Position: Q4 2023 in Review

Ensign Peak Advisors sold out of ACELYRIN (SLRN) in Q4 2023, closing a stake of 100,000 shares — an estimated $1.02M sold.

Ensign Peak Advisors first reported a position in SLRN in Q2 2023 and held it in 2 quarters. The position peaked at $2.09M in Q2 2023. 110 funds tracked by Wall St. Rank hold SLRN as of Q4 2023.

Ensign Peak Advisors reported no remaining ACELYRIN position as of Q4 2023 after selling out during the quarter.
Ensign Peak Advisors sold 100,000 ACELYRIN shares in Q4 2023, an estimated $1.02M.
Ensign Peak Advisors first reported a position in ACELYRIN in Q2 2023 and held it in 2 quarters.
Ensign Peak Advisors's ACELYRIN position peaked at $2.09M in Q2 2023.
110 funds tracked by Wall St. Rank held ACELYRIN as of Q4 2023.

Based on Ensign Peak Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.